Drug intelligence / Profile preview

I-IR799-CXB

Development stage: Preclinical
Lead developer: Suranaree University of Technology
Modality: Small Molecules

Overview

I-IR799-CXB is an experimental **heptamethine cyanine-based theranostic small-molecule conjugate** consisting of the near-infrared photosensitizer I-IR799 covalently linked to celecoxib. It was designed to preferentially target cyclooxygenase-2-expressing cancer cells and, following near-infrared light activation, mediate photodynamic therapy through phototoxic reactive-oxygen-species generation. The probe was reported in preclinical in-vitro studies of hepatocellular carcinoma HepG2 cells compared with normal AML12 liver cells.

Other names: I-IR799-CXBI-IR-799-CXBI-IR 799-CXB

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on I-IR799-CXB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on I-IR799-CXB.

Explore the full profile